# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0237 |
| Population Package | PP-0237 |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| No overlap with adjacent Population Packages | PASS |
| Locked PP-0112 decisions implemented | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with NCCN Gastric Cancer Version 2.2026 | PASS |
| Consistent with the locked PP-0111 architecture | PASS |
| Appropriate explanation of ctDNA | PASS |
| Appropriate distinction between ctDNA and liquid biopsy | PASS |
| Appropriate distinction between ctDNA and cfDNA | PASS |
| Appropriate explanation of blood-based genomic testing | PASS |
| Appropriate explanation of potentially targetable alterations | PASS |
| Appropriate explanation of tumor evolution | PASS |
| Appropriate treatment-response/resistance framing | PASS |
| Appropriate negative-result interpretation | PASS |
| No unsupported universal ctDNA monitoring claim | PASS |
| No unsupported MRD/recurrence algorithm | PASS |
| No unsupported numerical threshold | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for patients and caregivers | PASS |
| Medical terminology explained at first use | PASS |
| Learning objectives satisfied | PASS |
| Knowledge blocks independently retrievable | PASS |
| Common misconceptions addressed | PASS |
| Tissue versus ctDNA distinction is clear | PASS |
| Positive/negative result limitations explained | PASS |
| Avoids overstating clinical utility | PASS |
| Encourages discussion with healthcare professionals | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| Evidence traceability complete | PASS |
| Scope maintained | PASS |
| Knowledge Graph complete | PASS |
| Versioning complete | PASS |
| Repository compliant | PASS |
| Gold Population Package Specification v1.0 followed | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No unsafe medical advice | PASS |
| No individualized treatment recommendation | PASS |
| No implication that ctDNA replaces tissue diagnosis universally | PASS |
| No implication that negative ctDNA excludes cancer | PASS |
| No implication that every detectable alteration is actionable | PASS |
| No implication that ctDNA change alone proves treatment failure | PASS |
| Appropriate caution around emerging/context-dependent applications | PASS |
| No unsupported ctDNA thresholds | PASS |
| No disease-specific treatment algorithm | PASS |

---

# Educational Boundary Review

The Population Package successfully remains within the locked PP-0112 educational boundary.

## Included

- definition and origin of ctDNA;
- cfDNA versus ctDNA;
- blood-based molecular information;
- genomic alterations;
- selected gastric-cancer clinical contexts;
- limited tissue;
- potentially targetable alterations;
- tumor evolution;
- treatment-response/resistance concepts;
- longitudinal molecular information;
- tissue versus ctDNA testing;
- negative-result interpretation;
- limitations.

## Excluded

- detailed NGS methodology;
- cfDNA laboratory workflow;
- variant calling;
- bioinformatics;
- variant interpretation/classification;
- CTC;
- other liquid-biopsy analytes;
- detailed MRD algorithms;
- recurrence-surveillance algorithms;
- numerical thresholds;
- treatment-switch algorithms;
- individualized result interpretation.

The **Atomic Knowledge Principle** has been preserved.

---

# Adjacent-Package Boundary Review

| Adjacent Package | Boundary Result |
|------------------|-----------------|
| PP-0099 — Molecular Testing | No material duplication |
| PP-0101 — NGS | Technical sequencing workflow excluded |
| PP-0102 — Gene Panel Testing | Gene-panel methodology excluded |
| PP-0107 — Variant Interpretation | Interpretation/classification excluded |
| PP-0233 — Clinical Genomics | Clinical-genomics concept extended specifically to ctDNA |
| PP-0235 — Somatic Genetic Testing | ctDNA treated as a specimen/source-specific downstream application |
| PP-0236 — Liquid Biopsy | Broader liquid-biopsy concept retained in PP-0111; ctDNA-specific content placed here |

---

# Evidence Safety Review

The strongest direct gastric-cancer evidence is the NCCN Gastric Cancer guideline, which supports:

- blood-based ctDNA genomic assessment;
- detection of mutations, alterations, and gene fusions;
- potential identification of targetable alterations;
- information about tumor-clone evolution and altered treatment-response profiles;
- selected use when tissue is limited or traditional biopsy is not possible;
- cautious interpretation of negative results.

The package deliberately does not extrapolate these points into universal ctDNA screening, universal MRD surveillance, or automatic treatment-switch rules.

---

# Final Quality Decision

## PASS

PP-0112 satisfies the locked **Gold Population Package Specification v1.0** and the approved PP-0112 Discussion decisions.

Approved as the official Population Package for:

> **PP-0237 — Circulating Tumor DNA (ctDNA)**

---

# Reviewer Notes

This Population Package establishes the dedicated **ctDNA node** downstream of the project's liquid-biopsy and somatic-genomics architecture.

It preserves the intended knowledge hierarchy:

**Somatic Genetic Testing**
→ **Liquid Biopsy**
→ **Circulating Tumor DNA (ctDNA)**
→ **future specialized molecular monitoring / MRD / resistance applications**

The package is intentionally patient-facing and clinically governed. It explains the clinical meaning of ctDNA without becoming a technical sequencing manual, variant-interpretation package, or treatment algorithm.

The most important safety boundary is preserved:

> **A negative ctDNA/liquid-biopsy result does not exclude the presence of a tumor.**

The package is therefore **runtime-ready and repository-ready**.
